sunbet

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Á¬Ã¦ËÑË÷
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Éñ¾­µÝÖÊת´ïÒì³£µÄ¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > Éñ¾­µÝÖÊת´ïÒì³£µÄ¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó

ǰÑÔ

¾­µäÓÕ·¢ÐÔ¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó°üÀ¨DAÄ£×Ó¡¢¹È°±ËáÄ£×ÓºÍÉñ¾­Ö÷ÒªËØÄ£×Ó¡£

DAÄ£×ӵĽ¨ÉèÖ÷ÒªÀ´×ÔÒ©ÀíѧµÄ·¢Ã÷£¬DA¼Ù˵µÄ½¨ÉèÊÇ»ùÓÚÒÔÏÂÊÓ²ìÊÂʵ£ºÖÎÁƾ«ÉñÆÆËéÖ¢µÄÒ©Îï¾ùÄÜ×è¶ÏDAÊÜÌ壻ֱ½Ó»ò¼ä½Ó¼¤»îDAÊÜÌå¿ÉÔÚÕý·²ÈËÉíÉÏÓÕ·¢£¬²¢ÔÚ¾«ÉñÆÆËéÖ¢»¼ÕßÉíÉϼӾçÉñ¾­²¡ÐÔÖ¢×´¡£Òò´Ë£¬ÒÔΪ¾«ÉñÆÆËéÖ¢Ö¢×´ÊÇÒòÄÔÄÚDA¹ýÊ£»òÉñ¾­Ï¸°û¶ÔDAÃô¸ÐÐÔÔöÌíËùÖ¡£ÔçÆÚÒÔDAʧµ÷Ϊ»ù´¡µÄ¶¯ÎïÄ£×ÓÖ÷Òª¼¯ÖÐÔÚÓÉDAÊÜÌåÞ׿¹¼Á»ò¼¤¶¯¼ÁÓÕ·¢µÄÐÐΪÌåÏÖÉÏ¡£

?

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

×îÆÕ±éʹÓõÄÊÇͨ¹ý¾«ÉñÐË·ÜÐÔÒ©±½±û°·(amphetamine)À´ÓÕ·¢¶¯ÎïµÄÒì³£ÐÐΪ¡£±½±û°·Í¨¹ýÉñ¾­Ï¸°ûĤÉϵÄתÔËÌå»òÖ±½ÓÀ©É¢½ø×ÅÃÔ¾­Ï¸°ûºó£¬Óë°ûÄÚÈÏÕæÖü´æÉñ¾­µÝÖʵÄÄÒÅÝÉϵÄתÔËÌå2±¬·¢×÷Ó㬱½±û°·¸Ä±äÁ˵¥°·µÝÖÊ´ÓÄÒÅݵ½°ûÖʵÄÖØÐ·ÖÅÉ£¬ÆäЧ¹ûÊǰüÀ¨DAÔÚÄڵĵ¥°·Éñ¾­µÝÖʵÄŨ¶ÈÉý¸ß¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

Sprague-Dawley´óÊó£¬ÌåÖØ280~320g£¬ÐÛÐÔ£¬´óÊóÖðÈÕ¸¹Ç»×¢Éä±½±û°·0.5mg/kgÌåÖØ£¬Å¨¶ÈΪ0.1mg/ml£¬¸øÒ©ÈÝÁ¿Îª5ml/kgÌåÖØ£¬Ò»Á¬10Ìì¡£

¡¾Ä£×ÓÌØµã¡¿£º

Ä£×Ó×é´óÊóǰ¶îÒ¶DAº¬Á¿ÏÔÖø¸ßÓÚÕý³£×飬¶ø5-HTºÍÈ¥¼×ÉöÉÏÏÙËØº¬Á¿»®·ÖÏÔÖøµÍÓÚÕý³£×顣ͬʱ¼ì²â¼äÄÔ¡¢ÄԸɵĵ¥°·µÝÖʺ¬Á¿·¢Ã÷£¬Ä£×Ó×é´óÊóµÄDAºÍÈ¥¼×ÉöÉÏÏÙËØº¬Á¿ÏÔÖø¸ßÓÚÕý³£×飬¶ø5-HTº¬Á¿ÏÔÖøµÍÓÚÕý³£×é¡£±½±û°·¿ÉÒýÆð¶¯Îï¿Ì°åÐÐΪ¼°Ô˶¯Á¿ÔöÌíµÈÒì³£·´Ó¦¡£¸ø´óÊó×¢Éä±½±û°·Ê±·ºÆð¿Ì°åºÍתȦÐÐΪ£¬ÇÒÕâÖÖÐÐΪ¾ßÓÐÒ×·¢ÐÔ¡¢Ç¨ÑÓÐԺ;ÙÐÐÐÔ¼ÓÖØµÈÌØµã£¬¶øÕâÐ©ÌØµãÓëÈ˵ľ«ÉñÆÆËéÖ¢ÏàËÆ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

±½±û°·¶ÔÄö³ÝÀදÎïÐÐΪӰÏìµÄÑо¿Ö÷Òª¼¯ÖÐÓÚ×Ô¾õÐÔÔ˶¯µÄÔöÌíºÍ¿Ì°åÐÐΪÉÏ£¬Á鳤ÀදÎïµÄÑо¿°üÀ¨Óɱ½±û°·ÒýÆðµÄÐÐΪÒì³£ºÍÉç»áÇéÐμäÏ໥×÷ÓõÄת±ä¡£ÕâЩÑо¿¾ßÓÐÏ൱ˮƽµÄÕ¹ÍûЧ¶È£¬ÌØÊâÊÇÔÚÒ©Àíѧ·½ÃæµÄÕ¹ÍûÐÔ¡£ÖÐÄÔ±ßÑØDAϵͳ½éµ¼Á˵ͼÁÁ¿±½±û°·µÄ×Ô¾õÐÔÔ˶¯¼¤»îЧ¹û£¬¶øºÚÖÊÎÆ×´ÌåDAϵͳÔò½éµ¼Á˸߼¶Á¿±½±û°·µÄ¿Ì°åÐÐΪ£¬´ËЧӦÒÔΪÓ뿹Éñ¾­²¡Ò©ÎïÒýÆð×¶ÌåÍâϵ²»Á¼·´Ó¦Ïà¹Ø¡£±ðµÄ£¬ ±½±û°·Äܹ»ÒýÆð¸ÐÊÜÔ˶¯ÃÅ¿ØÕϰ­£¬Äö³ÝÀදÎï¿Éͨ¹ý¾ªÌø·´Ó¦µÄÂö³åǰÒÖÖÆÀ´¾ÙÐÐÆÀ¼Û¡£¶øÍ¨³£¾«ÉñÆÆËéÖ¢»¼Õß²¢ÎÞÔ˶¯Ì«¹ýµÄÌåÏÖ£¬Òò´Ë±½±û°·ÓÕ·¢µÄÌ«¹ýÔ˶¯ÄÑÒÔ×÷Ϊһ¸öÓÅÒìµÄÍâòЧ¶ÈÖ¸±ê¡£ÓÉÓÚ´ËÄ£×Ó¾ßÓÐÓÅÒìµÄ²¡ÒòѧЧ¶ÈºÍÕ¹ÍûЧ¶È£¬Ö»¹ÜÍâòЧ¶È²»¼Ñ£¬µ«Ò²²»Ê§ÎªÒ»¸öºÜºÃÓõÄÑо¿Ä£×Ó¡£ÐèÒª×¢ÖØÆäÒ©ÀíѧչÍûЧ¶È¾ÖÏÞÓÚDA»úÖÆ£¬Òò¶øºÜÄÑÃ÷ÊÍÓëDA»úÖÆ¹ØÏµ²»´óµÄÐÂÐÍ¿¹Éñ¾­²¡Ò©¡£ÔÙÕߣ¬ÓÉÓÚ±½±û°·¶ÔÄö³ÝÀදÎïµÄÉç»áÐÔÐÐΪ²»±¬·¢Ó°Ï죬Òò¶øÎÞ·¨ÓÃÓÚÄ£Ä⾫ÉñÆÆËéÖ¢µÄÒõÐÔÖ¢×´¡£

?

²Î¿¼ÎÄÏ×£º

1.ÍõÏþÁ¼£®´Þ¶«ºì£¬ËÚÓ×áÔ£®¶¯ÎïÄ£×ÓÔÚ¾«ÉñÆÆËéÖ¢Ñо¿ÖеÄÓ¦ÓÃÓëÏ£Íû£®ÖйúÒ½Ò©µ¼±¨£¬2012,9 (30):23-26

2.ÀîÏþ°×£¬·½êÝÈ壬Íõ׿³Ð£¬µÈ£®¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®ÉϺ£¾«Éñҽѧ£¬2004, 16(3): 184-186

3.Bertaina-Anglade V,Enjuanes E,Morillon D,el al. The object recognition Lask in rats anrl mice:a simple and rapid model in safety pharmacology lo detect amnesi properties of a new chemical entity. J Pharmacol Toxicol Methods, 2006, 54 (2):99-105

4.Jentsch JD, Roth RH. The neuropsypharmacology of phencyclidine: from NMDA receptor ?hypofunction ?lo the dopamine hypothesis of schizophrenia. Neurops-ychopharmacology, 1999,20 (3):201 -225

5.Kilts CD. The changing roles and targets for animal models of schizophrenia. Biol psychosis, 2001, 50 (11):845-855

6.Li Q,Cheung C, Wei R,el al. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant lo schizophrenia:evidence from MRI in a mouse model. PLoS One,2009,4(7):e6354

7.Semenova S,Ceyer MA,Sutcliffe JC,et al. Inaclivalion of the 5-HT7 receptor partiality blocks phencyclidineinduced disruption of prepulse inhibition. Biol Psychiatry, 2008, 63 (1):98-105

8.van Elst LT, Valerius G,Buchert M,et al. Incrased prefrontal and hippocampal glutamate ?concentration in schizophrenia:evidence from a magnetic resonance pectroscopy study. Biol Psychiatry, 2005,58 (9):724-730

sunbet(ÖйúÇø)¹Ù·½ÍøÕ¾Èë¿Ú
Ä£×ÓĿ¼
Ä¿½ñλÖãºÊ×Ò³ > ÈËÀ༲²¡¶¯ÎïÄ£×ÓĿ¼ > Éñ¾­ÏµÍ³Ä£×Ó > Éñ¾­µÝÖÊת´ïÒì³£µÄ¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó
Éñ¾­µÝÖÊת´ïÒì³£µÄ¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó

ǰÑÔ

¾­µäÓÕ·¢ÐÔ¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×Ó°üÀ¨DAÄ£×Ó¡¢¹È°±ËáÄ£×ÓºÍÉñ¾­Ö÷ÒªËØÄ£×Ó¡£

DAÄ£×ӵĽ¨ÉèÖ÷ÒªÀ´×ÔÒ©ÀíѧµÄ·¢Ã÷£¬DA¼Ù˵µÄ½¨ÉèÊÇ»ùÓÚÒÔÏÂÊÓ²ìÊÂʵ£ºÖÎÁƾ«ÉñÆÆËéÖ¢µÄÒ©Îï¾ùÄÜ×è¶ÏDAÊÜÌ壻ֱ½Ó»ò¼ä½Ó¼¤»îDAÊÜÌå¿ÉÔÚÕý·²ÈËÉíÉÏÓÕ·¢£¬²¢ÔÚ¾«ÉñÆÆËéÖ¢»¼ÕßÉíÉϼӾçÉñ¾­²¡ÐÔÖ¢×´¡£Òò´Ë£¬ÒÔΪ¾«ÉñÆÆËéÖ¢Ö¢×´ÊÇÒòÄÔÄÚDA¹ýÊ£»òÉñ¾­Ï¸°û¶ÔDAÃô¸ÐÐÔÔöÌíËùÖ¡£ÔçÆÚÒÔDAʧµ÷Ϊ»ù´¡µÄ¶¯ÎïÄ£×ÓÖ÷Òª¼¯ÖÐÔÚÓÉDAÊÜÌåÞ׿¹¼Á»ò¼¤¶¯¼ÁÓÕ·¢µÄÐÐΪÌåÏÖÉÏ¡£

?

²¿·ÖÔìÄ£ÒªÁì

ʹÓö¯Î´óÊó

¡¾ÔìÄ£»úÖÆ¡¿£º

×îÆÕ±éʹÓõÄÊÇͨ¹ý¾«ÉñÐË·ÜÐÔÒ©±½±û°·(amphetamine)À´ÓÕ·¢¶¯ÎïµÄÒì³£ÐÐΪ¡£±½±û°·Í¨¹ýÉñ¾­Ï¸°ûĤÉϵÄתÔËÌå»òÖ±½ÓÀ©É¢½ø×ÅÃÔ¾­Ï¸°ûºó£¬Óë°ûÄÚÈÏÕæÖü´æÉñ¾­µÝÖʵÄÄÒÅÝÉϵÄתÔËÌå2±¬·¢×÷Ó㬱½±û°·¸Ä±äÁ˵¥°·µÝÖÊ´ÓÄÒÅݵ½°ûÖʵÄÖØÐ·ÖÅÉ£¬ÆäЧ¹ûÊǰüÀ¨DAÔÚÄڵĵ¥°·Éñ¾­µÝÖʵÄŨ¶ÈÉý¸ß¡£

¡¾ÔìÄ£ÒªÁì¡¿£º

Sprague-Dawley´óÊó£¬ÌåÖØ280~320g£¬ÐÛÐÔ£¬´óÊóÖðÈÕ¸¹Ç»×¢Éä±½±û°·0.5mg/kgÌåÖØ£¬Å¨¶ÈΪ0.1mg/ml£¬¸øÒ©ÈÝÁ¿Îª5ml/kgÌåÖØ£¬Ò»Á¬10Ìì¡£

¡¾Ä£×ÓÌØµã¡¿£º

Ä£×Ó×é´óÊóǰ¶îÒ¶DAº¬Á¿ÏÔÖø¸ßÓÚÕý³£×飬¶ø5-HTºÍÈ¥¼×ÉöÉÏÏÙËØº¬Á¿»®·ÖÏÔÖøµÍÓÚÕý³£×顣ͬʱ¼ì²â¼äÄÔ¡¢ÄԸɵĵ¥°·µÝÖʺ¬Á¿·¢Ã÷£¬Ä£×Ó×é´óÊóµÄDAºÍÈ¥¼×ÉöÉÏÏÙËØº¬Á¿ÏÔÖø¸ßÓÚÕý³£×飬¶ø5-HTº¬Á¿ÏÔÖøµÍÓÚÕý³£×é¡£±½±û°·¿ÉÒýÆð¶¯Îï¿Ì°åÐÐΪ¼°Ô˶¯Á¿ÔöÌíµÈÒì³£·´Ó¦¡£¸ø´óÊó×¢Éä±½±û°·Ê±·ºÆð¿Ì°åºÍתȦÐÐΪ£¬ÇÒÕâÖÖÐÐΪ¾ßÓÐÒ×·¢ÐÔ¡¢Ç¨ÑÓÐԺ;ÙÐÐÐÔ¼ÓÖØµÈÌØµã£¬¶øÕâÐ©ÌØµãÓëÈ˵ľ«ÉñÆÆËéÖ¢ÏàËÆ¡£

¡¾Ä£×ÓÆÀ¹ÀºÍÓ¦Óá¿£º

±½±û°·¶ÔÄö³ÝÀදÎïÐÐΪӰÏìµÄÑо¿Ö÷Òª¼¯ÖÐÓÚ×Ô¾õÐÔÔ˶¯µÄÔöÌíºÍ¿Ì°åÐÐΪÉÏ£¬Á鳤ÀදÎïµÄÑо¿°üÀ¨Óɱ½±û°·ÒýÆðµÄÐÐΪÒì³£ºÍÉç»áÇéÐμäÏ໥×÷ÓõÄת±ä¡£ÕâЩÑо¿¾ßÓÐÏ൱ˮƽµÄÕ¹ÍûЧ¶È£¬ÌØÊâÊÇÔÚÒ©Àíѧ·½ÃæµÄÕ¹ÍûÐÔ¡£ÖÐÄÔ±ßÑØDAϵͳ½éµ¼Á˵ͼÁÁ¿±½±û°·µÄ×Ô¾õÐÔÔ˶¯¼¤»îЧ¹û£¬¶øºÚÖÊÎÆ×´ÌåDAϵͳÔò½éµ¼Á˸߼¶Á¿±½±û°·µÄ¿Ì°åÐÐΪ£¬´ËЧӦÒÔΪÓ뿹Éñ¾­²¡Ò©ÎïÒýÆð×¶ÌåÍâϵ²»Á¼·´Ó¦Ïà¹Ø¡£±ðµÄ£¬ ±½±û°·Äܹ»ÒýÆð¸ÐÊÜÔ˶¯ÃÅ¿ØÕϰ­£¬Äö³ÝÀදÎï¿Éͨ¹ý¾ªÌø·´Ó¦µÄÂö³åǰÒÖÖÆÀ´¾ÙÐÐÆÀ¼Û¡£¶øÍ¨³£¾«ÉñÆÆËéÖ¢»¼Õß²¢ÎÞÔ˶¯Ì«¹ýµÄÌåÏÖ£¬Òò´Ë±½±û°·ÓÕ·¢µÄÌ«¹ýÔ˶¯ÄÑÒÔ×÷Ϊһ¸öÓÅÒìµÄÍâòЧ¶ÈÖ¸±ê¡£ÓÉÓÚ´ËÄ£×Ó¾ßÓÐÓÅÒìµÄ²¡ÒòѧЧ¶ÈºÍÕ¹ÍûЧ¶È£¬Ö»¹ÜÍâòЧ¶È²»¼Ñ£¬µ«Ò²²»Ê§ÎªÒ»¸öºÜºÃÓõÄÑо¿Ä£×Ó¡£ÐèÒª×¢ÖØÆäÒ©ÀíѧչÍûЧ¶È¾ÖÏÞÓÚDA»úÖÆ£¬Òò¶øºÜÄÑÃ÷ÊÍÓëDA»úÖÆ¹ØÏµ²»´óµÄÐÂÐÍ¿¹Éñ¾­²¡Ò©¡£ÔÙÕߣ¬ÓÉÓÚ±½±û°·¶ÔÄö³ÝÀදÎïµÄÉç»áÐÔÐÐΪ²»±¬·¢Ó°Ï죬Òò¶øÎÞ·¨ÓÃÓÚÄ£Ä⾫ÉñÆÆËéÖ¢µÄÒõÐÔÖ¢×´¡£

?

²Î¿¼ÎÄÏ×£º

1.ÍõÏþÁ¼£®´Þ¶«ºì£¬ËÚÓ×áÔ£®¶¯ÎïÄ£×ÓÔÚ¾«ÉñÆÆËéÖ¢Ñо¿ÖеÄÓ¦ÓÃÓëÏ£Íû£®ÖйúÒ½Ò©µ¼±¨£¬2012,9 (30):23-26

2.ÀîÏþ°×£¬·½êÝÈ壬Íõ׿³Ð£¬µÈ£®¾«ÉñÆÆËéÖ¢¶¯ÎïÄ£×ÓÑо¿Ï£Íû£®ÉϺ£¾«Éñҽѧ£¬2004, 16(3): 184-186

3.Bertaina-Anglade V,Enjuanes E,Morillon D,el al. The object recognition Lask in rats anrl mice:a simple and rapid model in safety pharmacology lo detect amnesi properties of a new chemical entity. J Pharmacol Toxicol Methods, 2006, 54 (2):99-105

4.Jentsch JD, Roth RH. The neuropsypharmacology of phencyclidine: from NMDA receptor ?hypofunction ?lo the dopamine hypothesis of schizophrenia. Neurops-ychopharmacology, 1999,20 (3):201 -225

5.Kilts CD. The changing roles and targets for animal models of schizophrenia. Biol psychosis, 2001, 50 (11):845-855

6.Li Q,Cheung C, Wei R,el al. Prenatal immune challenge is an environmental risk factor for brain and behavior change relevant lo schizophrenia:evidence from MRI in a mouse model. PLoS One,2009,4(7):e6354

7.Semenova S,Ceyer MA,Sutcliffe JC,et al. Inaclivalion of the 5-HT7 receptor partiality blocks phencyclidineinduced disruption of prepulse inhibition. Biol Psychiatry, 2008, 63 (1):98-105

8.van Elst LT, Valerius G,Buchert M,et al. Incrased prefrontal and hippocampal glutamate ?concentration in schizophrenia:evidence from a magnetic resonance pectroscopy study. Biol Psychiatry, 2005,58 (9):724-730

¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿